Using cannabidiol and buprenorphine to improve treatment for opioid use disorder
Cannabidiol and buprenorphine: A poly-pharmacy approach to treat opioid use disorder
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-11165968
This study is looking at whether combining CBD with lower doses of buprenorphine can help people with opioid use disorder feel better and stick with their treatment while experiencing fewer side effects.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-11165968 on ClinicalTrials.gov |
What this research studies
This research investigates the combined use of cannabidiol (CBD) and buprenorphine to enhance treatment outcomes for individuals with opioid use disorder (OUD). The study aims to determine if CBD can safely improve the effectiveness of lower doses of buprenorphine, which is commonly prescribed for OUD but often leads to treatment discontinuation due to side effects at higher doses. By exploring this poly-pharmacy approach, the research seeks to reduce cravings and improve retention in treatment without increasing adverse effects. Patients will be monitored for their response to this combination therapy over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are currently prescribed buprenorphine.
Not a fit: Patients who are not diagnosed with opioid use disorder or those who are not currently on buprenorphine treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients struggling with opioid use disorder.
How similar studies have performed: Previous research has shown promising results with the use of cannabinoids as adjunctive treatments for substance use disorders, suggesting potential for success in this approach.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GALBO THOMMA, LINDSEY — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: GALBO THOMMA, LINDSEY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.